122 related articles for article (PubMed ID: 8162642)
1. The treatment of Sjögren's disease in NZB/NZW F1 hybrid mice with azathioprine: a two-stage study.
Yeoman CM; Franklin CD
Clin Exp Rheumatol; 1994; 12(1):49-53. PubMed ID: 8162642
[TBL] [Abstract][Full Text] [Related]
2. Assessment of sulphasalazine as a treatment modality in Sjögren's disease in NZB/NZW F1 hybrid mice.
Yeoman CM; Franklin CD
Clin Exp Rheumatol; 1996; 14(1):53-7. PubMed ID: 8697658
[TBL] [Abstract][Full Text] [Related]
3. Effect of nandrolone decanoate on Sjögren's syndrome like disorders in NZB/NZW mice.
Schot LP; Verheul HA; Schuurs AH
Clin Exp Immunol; 1984 Sep; 57(3):571-4. PubMed ID: 6467680
[TBL] [Abstract][Full Text] [Related]
4. Testosterone-induced suppression of autoimmune disease in lacrimal tissue of a mouse model (NZB/NZW F1) of Sjögren's syndrome.
Vendramini AC; Soo C; Sullivan DA
Invest Ophthalmol Vis Sci; 1991 Oct; 32(11):3002-6. PubMed ID: 1917404
[TBL] [Abstract][Full Text] [Related]
5. Sjögren's syndrome in mice carrying the Ipr(cg) gene and the therapeutic efficacy of an immunosuppressive agent FK506.
Yang J; Shikata N; Yasuda T; Matsuzawa A; Tsubura A
Pathol Int; 1999 Feb; 49(2):133-40. PubMed ID: 10355966
[TBL] [Abstract][Full Text] [Related]
6. Lacrimal gland fluid secretion and lymphocytic infiltration in the NZB/W mouse model of Sjögren's syndrome.
Paranyuk Y; Claros N; Birzgalis A; Moore LC; Brink PR; Walcott B
Curr Eye Res; 2001 Sep; 23(3):199-205. PubMed ID: 11803482
[TBL] [Abstract][Full Text] [Related]
7. Sjögren's syndrome in MRL/l and MRL/n mice.
Hoffman RW; Alspaugh MA; Waggie KS; Durham JB; Walker SE
Arthritis Rheum; 1984 Feb; 27(2):157-65. PubMed ID: 6421291
[TBL] [Abstract][Full Text] [Related]
8. Lacrimal gland, cornea, and tear film in the NZB/NZW F1 hybrid mouse.
Gilbard JP; Hanninen LA; Rothman RC; Kenyon KR
Curr Eye Res; 1987 Oct; 6(10):1237-48. PubMed ID: 3677784
[TBL] [Abstract][Full Text] [Related]
9. Exocrinopathy resembling Sjögren's syndrome induced by a murine retrovirus.
Suzuki K; Makino M; Okada Y; Kinoshita J; Yui R; Kanazawa H; Asakura H; Fujiwara M; Mizuochi T; Komuro K
Lab Invest; 1993 Oct; 69(4):430-5. PubMed ID: 8231110
[TBL] [Abstract][Full Text] [Related]
10. Murine models of Sjögren's syndrome. Evolution of the lacrimal gland inflammatory lesions.
Jabs DA; Enger C; Prendergast RA
Invest Ophthalmol Vis Sci; 1991 Feb; 32(2):371-80. PubMed ID: 1993589
[TBL] [Abstract][Full Text] [Related]
11. Comparative influence of steroid hormones and immunosuppressive agents on autoimmune expression in lacrimal glands of a female mouse model of Sjögren's syndrome.
Sato EH; Sullivan DA
Invest Ophthalmol Vis Sci; 1994 Apr; 35(5):2632-42. PubMed ID: 8163351
[TBL] [Abstract][Full Text] [Related]
12. Destruction of salivary and lacrimal glands by Th1-polarized reaction in a model of secondary Sjögren's syndrome in lupus-prone female NZB × NZWF(1) mice.
Hayashi T; Shimoyama N; Mizuno T
Inflammation; 2012 Apr; 35(2):638-46. PubMed ID: 21786007
[TBL] [Abstract][Full Text] [Related]
13. Influence of androgen therapy on lacrimal autoimmune disease in a mouse model of Sjögren's syndrome.
Sullivan DA; Rocha FJ; Sato EH
Adv Exp Med Biol; 1995; 371B():1199-202. PubMed ID: 7502783
[No Abstract] [Full Text] [Related]
14. IL-14 alpha, the nexus for primary Sjögren's disease in mice and humans.
Shen L; Suresh L; Li H; Zhang C; Kumar V; Pankewycz O; Ambrus JL
Clin Immunol; 2009 Mar; 130(3):304-12. PubMed ID: 19038581
[TBL] [Abstract][Full Text] [Related]
15. Assessment of bromhexine as a treatment regimen in Sjögren's syndrome-like disease in the NOD (non-obese diabetic) mouse.
Nanni JM; Nguyen KH; Alford CE; Robinson CP; Stewart CM; Maeda N; Humphreys-Beher MG
Clin Exp Rheumatol; 1997; 15(5):515-21. PubMed ID: 9307859
[TBL] [Abstract][Full Text] [Related]
16. Impact of gender on exocrine gland inflammation in mouse models of Sjögren's syndrome.
Toda I; Sullivan BD; Rocha EM; Da Silveira LA; Wickham LA; Sullivan DA
Exp Eye Res; 1999 Oct; 69(4):355-66. PubMed ID: 10504269
[TBL] [Abstract][Full Text] [Related]
17. Temporal histological changes in lacrimal and major salivary glands in mouse models of Sjogren's syndrome.
Xuan J; Shen L; Malyavantham K; Pankewycz O; Ambrus JL; Suresh L
BMC Oral Health; 2013 Oct; 13():51. PubMed ID: 24093879
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory stimuli accelerate Sjögren's syndrome-like disease in (NZB x NZW)F1 mice.
Deshmukh US; Ohyama Y; Bagavant H; Guo X; Gaskin F; Fu SM
Arthritis Rheum; 2008 May; 58(5):1318-23. PubMed ID: 18438852
[TBL] [Abstract][Full Text] [Related]
19. Quantitative and visual evaluation of salivary and thyroid glands in patients with primary Sjögren's syndrome using salivary gland scintigraphy: relationship with clinicopathological features of salivary, lacrimal and thyroid glands.
Güne S; Yilmaz S; Karalezli A; Aktaş A
Nucl Med Commun; 2010 Jul; 31(7):666-72. PubMed ID: 20545046
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of nandrolone decanoate, tibolone, lynestrenol and ethylestrenol on Sjögren's syndrome-like disorder in NZB/W mice.
Verheul HA; Schot LP; Schuurs HW
Clin Exp Immunol; 1986 May; 64(2):243-8. PubMed ID: 3742875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
